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Abstract 
Tumor necrosis factor ( T N F ) has been determined as an endogenous mediator for endo-
toxin-induced tumor necrosis. This macrophage product has been biochemically characterized 
and its protein structure defined by molecular cloning of the T N F gene. Experiments with 
antibodies to T N F demonstrated that T N F acts as an effector molecule of activated cytotoxic 
macrophages involved in tumor destruction. 
Purified T N F has been shown to exert direct necrotic activity against tumors in vivo. In 
addition, a number of similar effects in vivo and in vitro of T N F , endotoxin, and interleukin 1 
(IL1) have been observed. For example, in vivo the thermoregulatory activity of T N F is 
similar to I L L Since T N F was found to mediate other effects of endotoxin in modulating 
immune responses in addition to the tumor necrotic activity, it can be considered a true 
immunoregulator produced by macrophages after endotoxin stimulation. 
Introduction 
The endotoxin-induced tumor necrosis phenomenon has been the subject 
of intensive clinical, biological, and biochemical research for many decades 
(1, 2). Numerous attempts have been undertaken to separate the beneficial 
tumor cytotoxic effects of endotoxin from the harmful pathophysiological 
endotoxic effects. Elucidation of the lipid A structure as the endotoxic 
principle of bacterial lipopolysaccharide (LPS) revealed the chemical struc-
ture responsible for the tumor necrosis eliciting activity (3, 4). However, 
due to the work of OLD et al. (5), it became obvious that the LPS-induced 
tumor necrosis was not a direct effect of LPS or lipid A on the tumor mass 
but rather an indirect phenomenon. An endogenous mediator, termed 
tumor necrosis factor (TNF), was elicited as a second messenger by LPS 
injection of animals with an activated reticular endothelial system. 
Characterization of the producer cells for TNF, requirements for T N F 
production and molecular cloning of the T N F genes in different species 
made clear that activated macrophages are a source for T N F (6, 7). The 
recombinant form of the T N F molecule was found as a 17,000 D protein in 
the case of human T N F (8). The amino acid sequence of the human T N F 
Abbreviations: BCG = Mycobacterium bovis; IFN = interferon; IL 1 = interleukin 1; LPS 
= lipopolysaccharide; TNF = tumor necrosis factor. 
showed about 80 % homology with murine T N F . In contrast to the human 
T N F , murine T N F contained one potential N-glycosylation site (9). The 
activity of T N F seemed not to be species-specific. 
Besides the tumor necrotic activity in vivo of T N F , a rather selective 
tumor cytotoxic activity of T N F has been observed and used as a sensitive 
in vitro test system. With the availability of purified and/or recombinant 
T N F , a number of biological T N F activities have been determined. Even 
though T N F was characterized as the endogenous mediator of endotoxin-
induced tumor necrosis, it has not been possible to separate the beneficial 
tumor necrotic effect as a distinct quality from all the other endotoxic 
activities. 
Materials and Methods 
Mice 
Male and female C 3 H / H e mice, 6 to 10 weeks of age, were obtained from Charles River 
Wiga, Sulzfeld, F . R . G . , and C 3 H / H e J mice were purchased from Jackson Laboratories, Bar 
Harbor , M E , U . S . A . 
Reagents 
Recombinant human T N F was generously supplied by B A S F , Ludwigshafen, F . R . G . , and 
recombinant I F N - y (produced by Genetech, Inc.) by Boehringer Ingelheim. Mycobacterium 
bovis, strain B C G (Phipps substrain, T C M 1029, Trudeau Mycobacterial Collect ion, Saranac 
Lake, N Y , U . S . A . ) , pyran copolymer (National Cancer Institute, Bethesda, M D , U . S . A . ) , 
Corynebacterium parvum (Wellcome Research Laboratories, Beckenham, England) and latex 
beads (1-um polystyrene beads, D o w Chemical C o . , M i d l a n d , M I , U . S . A . ) were injected 
intraperitoneal^ to activate macrophages. 
Assays for TNF 
T N F samples were cultured with 4 X 103 ( 3 H)TdR-prelabeled L929 tumor cells for 48 h in a 
culture volume of 0.2 m l . Cytotoxici ty was estimated by measuring release of ( 3 H ) T d R from 
tumor cells and expressed as % release of total incorporated counts. In another test system, 
T N F samples were cultured with 2 X 104 L929 tumor cells for 24 h in 0.2 m l cultures in the 
presence of actinomycin D (2 ug/ml), and viable cells were determined by staining with crystal 
violet. 
Macrophage cytotoxicity assay 
( 3 H)TdR-prelabeled tumor cells (6 X 103 L929 or 1023 fibrosarcoma cells) were cultured 
together with 1.2 X 105 peritoneal exudate cells in 0.2 ml cultures for 48 h . Cytotoxici ty was 
estimated by measuring release of ( 3 H ) T d R from tumor cells and expressed as % release of 
total incorporated counts. 
Blood parameters 
Plasma glucose levels were determined with a Gluco-Quant glucose kit , and plasma lactate 
levels were measured with a Monotest-Lactat kit (both from Boehringer, Mannheim, F . R . G . ) . 
Results 
TNF as a tumor cytotoxic effector molecule of activated macrophages 
The mechanism of tumor cell destruction by activated macrophages is not 
well understood. Cell contact of macrophages with tumor cells seemed to 
be required, and no soluble cytotoxic activity was measurable in conven-
tional macrophage cytotoxicity assays. However, when macrophages are 
activated they become extremely sensitive to lipid A stimulation (10). 
Therefore, we investigated the production of T N F by murine macrophages 
upon LPS exposure and compared the TNF-producing ability with the 
tumoricidal capacity of these macrophages. Release of T N F from mac-
rophages upon LPS stimulation was only observed when the macrophages 
had been appropriately activated before. The activation correlated with the 
potential of the macrophages for tumor cytotoxicity (Table 1). Thus, only 
tumor cytotoxic macrophages were able to secrete T N F into the medium as 
a response to LPS. This indicated a possible role of T N F in macrophage 
tumor destruction. 
Rabbit antibodies directed against semipurified murine T N F have been 
generated and had good TNF-neutralizing activity (11). These antibodies 
were also capable of inhibiting macrophage tumor cytotoxicity (Table 2), 
even though no soluble T N F was found in the supernatants of these 
cytotoxic macrophages in the absence of added LPS. Culture morphology 
demonstrated an even more striking inhibition of macrophage tumor cell 
destruction by the T N F antibodies. Cultures of activated macrophages and 
tumor cells showed a strong cytopathic effect, whereas in identical cultures 
Table 1. Correlation between macrophage tumoricidal activity and release of T N F 
Macrophages from 
mice treated w i t h a 
Macrophage 
activity15 (%) 
tumoricidal 
i 
Release of T N F C 
(% cytotoxic activity) 
- L P S + LPS 
B C G 
Pyran 
C. parvum 
PBS 
Starch 
Latex 
26 
27 
23 
9 
7 
9 
11 
15 
13 
8 
8 
8 
33 
38 
39 
11 
8 
9 
a Adherent peritoneal exudate cells were used from mice treated i.p. with 2 X 106 viable B C G , 
500 jAg of pyran, 1.4 mg of C. parvum, 2 % starch in water, latex beads 7 days previously or 
with PBS 1 day previously. 
b Macrophage tumoricidal activity (released ( 3 H)TdR) was estimated after 48 h of coculture 
with ( 3 H ) T d R prelabeled tumor cells and expressed as a percentage of total incorporated 
label. 
c For release of T N F the cytotoxic activity of 2 h supernatants was tested on prelabeled tumor 
cells as in b . 
Table 2 . Inhibition of macrophage cytotoxicity by rabbit IgG against T N F 
Stimulus Cytotoxicity* (%) 
C o n t r o l a n t i - T N F 
B C G 8 9 4 0 
Pyran 8 6 4 7 
C. parvum 9 0 6 4 
a Adherent peritoneal exudate cells from mice treated as indicated in the footnote to Table 1 
were used. Tumoricidal activity was determined as in Table 1. 
but in the presence of anti-TNF the tumor cell density was as high as in the 
presence of non-activated macrophages. These results not only suggested 
participation of T N F in macrophage tumor cytotoxicity, but they also 
implied that this had to occur in a short-range or even membrane-bound 
fashion. 
TNF as mediator of endotoxin effects 
With the availability of purified recombinant T N F , in vivo effects after 
application of relatively large quantities of this mediator could be studied. 
Intravenous injection of T N F (3-4 mg/kg) into endotoxin-sensitive C 3 H / 
He or endotoxin low responder C3H/HeJ mice induced a dramatic impair-
ment of well-being of the animals of both strains within 30 min. Hunched 
back, ruffled fur and diarrhea were the immediate, obvious symptoms. The 
body temperature of these animals dropped from normal 38 °C to 30 °C and 
below within 5 h after intravenous T N F application, and some animals 
died. The time course of decrease of the temperature paralleled the tempera-
ture decrease induced by LPS in endotoxin-sensitive C3H/He mice (12) 
(Table 3). However, this effect was not due to endotoxin contamination of 
the T N F preparation, since this temperature decrease was also observed in 
the endotoxin low-responder mouse strain. 
Table 3 . Body temperature changes in mice after T N F or L P S injection 
Stimulus Temperature (°C) a 
hours post injection 
0 3 6 2 4 4 8 
T N F 38.1 3 0 . 3 2 9 . 5 3 4 . 7 3 5 . 2 
( - 7 . 8 ) ( - 8 . 6 ) ( - 3 . 4 ) ( - 2 . 9 ) 
L P S 3 7 . 4 3 3 . 4 3 2 . 9 3 6 . 0 3 5 . 5 
( - 4 . 0 ) ( - 4 . 5 ) ( - 1 . 4 ) ( - 1 . 9 ) 
a Rectal temperatures of C 3 H / H e mice after i .v. injection of T N F ( 1 0 0 u.g) or L P S ( 2 0 0 jig) 
were measured. Numbers in parentheses indicate the temperature change. 
Changes of blood and plasma parameters that are typical for endotoxin 
were observed after T N F application (13, 14). Hematocrit levels were 
significantly increased after 30 min, plasma lactate levels were also increased 
after 6 h, and plasma glucose levels decreased after 6 h. These data indicated 
that T N F mediated the pathophysiological effects of endotoxin. This 
observation is supported by the data of B E U T L E R et al. (15), which 
demonstrated that antibodies to cachectin (which is probably identical with 
T N F (16)) protected mice from the lethal effects of endotoxin. 
TNF as immunomodulator 
Besides the well-known effect of induction of tumor necrosis and in vitro 
tumor cytotoxicity by TNF, a number of other biological effects on 
different cell types have been published. Collagenase and prostaglandin E 2 
production by human synovial cells and dermal fibroblasts (17), activation 
of polymorphonuclear neutrophil function (18), enhancement of surface 
expression of class I major histocompatibility complex antigens in vascular 
endothelial cells and dermal fibroblasts (19), stimulation of neutrophil 
adherence to umbilical vein endothelium (20), stimulation of bone resorp-
tion and inhibition of bone formation (21) are only some of these T N F 
activities. From observations in a number of different laboratories, it 
became obvious that T N F exhibits an even greater variety of effects. 
Synergistic action of T N F and interferon-y (IFN-y) in tumor cytotoxic 
activity has been documented with a number of different target cells (22). 
Table 4 demonstrates the increased T N F sensitivity of human HeLa cells 
and mouse L929 fibrosarcoma cells when pretreated with IFN-y. In addi-
tion, the production of T N F is enhanced by IFN-y (23). Taken together, 
these effects demonstrate an effective amplification mechanism for T N F 
function by IFN-y. 
T N F itself was also able to regulate the sensitivity of tumor cells to the 
cytotoxic effect of T N F (Table 5). Higher concentrations of T N F were 
required to induce 50 % reduction in cell viability when the sensitive L929 
cells had been exposed to T N F previously. Also, this protective effect was 
up to a certain concentration dose dependent. There were two likely 
Table 4. Influence of I F N - y pretreatment on the TNF-sensitivity of tumor cells in vitro 
I F N - y (U/ml) 50 % survival 1 (ng T N F / m l ) 
H e L a L929 
0 
10 
100 
1.5 0.5 
n.d. 0.125 
0.15 0.125 
a H e L a or L929 cells were cultured for 16 h in different concentrations of recombinant human 
or murine I F N , respectively. 50 % survival of the cells was determined by 24 h exposure to 
different concentrations of recombinant T N F in the presence of actinomycin D . 
Table 5. Influence of TNF-pretreatment on the sensitivity of tumor cells 
T N F (ng/ml) 50 % survival 3 
(ng T N F / m l ) 
0 0.3 
1 2.5 
10 5.0 
3 L929 cells were cultured for 16 h in different concentrations of recombinant T N F . 5 0 % 
survival of the cells was determined by 24 h exposure to different concentrations of T N F in 
the presence of actinomycin D . 
explanations for these observations. One could be the selective killing of the 
most sensitive cells by the pretreatment, leaving the least sensitive cells 
behind. The second possibility is that T N F induces a protective state in the 
cells. A similar self-resistance-induction has already been described for 
lymphotoxin (24). These observations indicate that the cytotoxic effect of 
T N F can be regulated by IFN-y and T N F . It remains to be tested whether 
other T N F activities such as prostaglandin-production, which can regulate 
immune functions, undergo similar regulation. 
Discussion 
Lipid A is the structure responsible for the beneficial and harmful 
biological properties of bacterial endotoxin (3). Macrophages are exquisite 
responder cells to lipid A and react even more strongly when they are in an 
activated stage (10). Therefore, the idea has developed that endotoxin may 
cause its pathophysiological effects through interaction with this cell type 
and eventually via macrophage-derived mediators such as T N F and I L L 
The array of functions of T N F and IL 1 seems to be very similar (with the 
exception of the effects of IL 1 on T cells). A number of endotoxic effects 
can be induced with pure preparations of IL 1 or T N F . A clear picture of 
the molecular mechanisms underlying the mediation of endotoxin effects 
will probably emerge from ongoing studies with these mediators. 
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